SCHEMBL14224534

SCHEMBL14224534

Cn1cc(NC(=O)c2cc3ccccc3cn2)cc1C(=O)Nc1cc(-c2nc3cc(NC(=O)C(F)(F)F)ccc3[nH]2)n(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
MAPK1 P28482 2/20 0.40
CBLB Q13191 7/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
FLT3 P36888 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
EGFR P00533 1/20 0.37
USP2 O75604 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14427363 0.88 MAPT (0.39) MAPTMAPK1CBLBCSF1RRET
SCHEMBL14426980 0.88 MAPT (0.39) MAPTMAPK1CBLBCSF1RRET
SCHEMBL14224537 0.87 MAPT (0.39) MAPTMAPK1CBLBCSF1RRET
SCHEMBL14224528 0.83 KDM4E (0.43) RAB9ANPC1HTTKDM4EALDH1A1
SCHEMBL14426984 0.83 MAPT (0.41) MAPTMAPK1CBLBCSF1RRET
SCHEMBL14224673 0.79 PDGFRB (0.45) PDGFRBPDGFRARAB9ANPC1KDM4E
SCHEMBL14224524 0.76 MAPT (0.37) MAPTMAPK1CBLBRAB9ANPC1
SCHEMBL14426911 0.75 RAB9A (0.44) MAPTMAPK1RAB9ASMN1; SMN2KDM4E
SCHEMBL13520198 0.72 EGFR (0.49) CBLBCSF1RRETPDGFRBKIT
SCHEMBL14224502 0.72 MAPT (0.49) MAPTMAPK1RAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS GENESOFT PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed
US-7265129-B2 Anti-infective biaryl compounds GENESOFT PHARMACEUTICALS, INC. (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS QTRT1, Q6ZSR9, QTRT2 MAPT 4305/4885MAPK1 4075/4885CBLB 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.